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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Lamivudine has been recommended as prophylaxis for the reactivation
of hepatitis B virus (HBV) infection in patients undergoing chemotherapy. However, informa-
tion on breast cancer patients in particular has been lacking. The purpose of this meta-
analysis was to assess the overall efficacy of lamivudine prophylaxis compared to untreated
patients with hepatitis B S-antigen (HBsAg) seropositive breast cancer who had undergone
chemotherapy.
Methods: Studies that compared the efficacy of treatment with lamivudine prophylaxis versus
no prophylaxis in HBsAg seropositive breast cancer patients were identified through Medline,
Cochrane, and Embase databases.
Results: Six studies involving 499 patients were analyzed. The rates of HBV reactivation in
patients with lamivudine prophylaxis were significantly lower than those with no prophylaxis
(risk ratio [RR] Z 0.23, 95% confidence interval [CI]: 0.13e0.39, p < 0.00001). Patients given
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Lamivudine prophylaxis in hepatitis B reactivation 165compared with those not given treatment (RR Z 0.20, 95% CI: 0.08e0.47, p Z 0.002). The
rates of moderate and severe hepatitis in patients with lamivudine prophylaxis were signifi-
cantly lower compared with those patients who had not received prophylaxis (RR Z 0.25,
95% CI: 0.10e0.62, p < 0.003; RRZ 0.25, 95% CI: 0.10e0.59, pZ 0.002). Patients given lami-
vudine prophylaxis had significantly fewer disruptions of chemotherapy (RR Z 0.36, 95% CI:
0.21e0.64, p Z 0.0004). There was no significant heterogeneity in the comparisons.
Conclusion: Lamivudine prophylaxis in HBsAg seropositive breast cancer patients undergoing
chemotherapy is effective in reducing HBV reactivation and HBV-associated morbidity and
mortality.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Hepatitis B virus (HBV) infection is a major global public and
medical concern. Seventy-five percent of infected individ-
uals live in Southeast Asia and the western Pacific regions.
Chronic carriers comprise more than 8% of the population in
these regions.1,2 The incidence of breast cancer (BC) is rising
rapidly, especially in developing countries, in areas highly
endemic with HBV, and therefore a high percentage of
cancer patients (up to 12%) are chronic carriers of HBV.3,4
It iswell recognized thatpatientswhohaveahistoryofHBV
infection are vulnerable to hepatitis flares during immuno-
suppressive or cytotoxic chemotherapy.5e7 Exacerbation of
hepatitis B canbea serious cause ofmorbidity andmortality in
cancer patients undergoing chemotherapy. The clinical
consequences vary from anicteric hepatitis to progressive
hepatic failure.8e11 Several mechanisms have been postu-
lated for HBV flare-ups, such as chemotherapy-enhanced viral
replication, corticosteroid-containing regimens, or return of
immune competence after completion of chemotherapy.12,13
Over the few past decades, chemotherapy has played an
important role in prolonging survival in BC patients. In
patients receiving chemotherapy for BC, the incidence of
HBV reactivation has been reported to be as high as
41e56%.14e16 As an oral nucleoside reverse transcriptase
inhibitor with activity against hepatitis B, lamivudine is
effective in rapidly decreasing viral load, and is associated
with few adverse effects.17e21 Previous studies have
demonstrated that lamivudine prophylaxis can effectively
prevent HBV reactivation and its associated fatality during
chemotherapy. A meta-analysis 22 by Lenna et al showed
that patients given lamivudine prophylaxis had reductions
of 87%, 70%, and 92% in HBV reactivation, reactivation-
related mortality, and chemotherapy disruptions, respec-
tively, compared with those patients not given prophylaxis.
However, these studies were mainly based on patients with
hematological malignancies. There have been few studies
on BC patients. Several studies have reported on prophy-
laxis in hepatitis B S-antigen (HBsAg) seropositive BC
patients who had undergone chemotherapy. In these
studies, however, there were still several inconsistencies in
the outcomes of hepatitis flares, HBV reactivation, reduc-
tion in the severity of hepatitis, and disruptions of
chemotherapy between patients receiving lamivudine
prophylaxis and those not treated.15,23e26.
The purpose of this meta-analysis was to evaluate the
efficacy of lamivudine prophylaxis on HBsAg seropositive BC
patients undergoing chemotherapy.Materials and methods
Literature search
Relevant studies were identified by searching Medline,
Embase, and the Cochrane databases. The search strategy
involved selecting subject headings and keywords used in
combination or alone: lamivudine, cytotoxic chemo-
therapy, HBV, HBsAg, reactivation, flare, prophylaxis,
breast cancer patients. The scope of the search was
restricted to “human” and “English”. We included all
randomized controlled trials; cohort trials; and prospec-
tive, controlled, non-randomized trials. The search was
carried out in March 2012, without a prior date limit for the
search results. A detailed manual reference search of all
relevant articles and reviews discovered in the database
was used to identify potentially relevant articles missed by
the computer search.
Inclusion and exclusion criteria
Inclusion criteria for the meta-analysis were as follows: (1)
randomized controlled cohort, retrospective comparative
case series and prospective, controlled, non-randomized
studies; (2) studies including a lamivudine prophylaxis
group and a non-prophylaxis group; and (3) all BC patients
in the two groups had undergone chemotherapy and were
seropositive for HBsAg. Patient populations were excluded
if: (1) reactivation/flares were not related to HBV, or the
HBV reactivation/flare was not a specific outcome of the
study; (2) there was no immunosuppressive or cytotoxic
therapy; (3) the study involved human immunodeficiency
virus (HIV) co-infection; (4) the study included patients who
had hepatitis D virus, hepatitis C virus or other liver
diseases; (5) the study did not have a lamivudine prophy-
laxis or a treatment regimen; or (6) did not have a lam-
ivudine prophylaxis and non-prophylaxis group. Any dataset
for which insufficient analytic information was available
was also excluded from the meta-analysis.
Efficacy measures
Hepatitis was defined as alanine aminotransferase (ALT)
3  upper limit of normal or a >100 U/L increase over
baseline based on a definition initially described by Lok
et al and subsequently modified by Yeo et al.4,27 Hepatitis
attributable to HBV reactivation was defined as an increase
166 J.-Y. Liu et al.in the HBV DNA level of 10-fold or more when compared
with the baseline level or an absolute increase of the HBV
DNA level that exceeded 1  109 copies/ml in the absence
of any other systemic infection. The severity of hepatitis
was defined as mild when the rise in ALT was 2  UNL,
moderate when ALT > 2 and 5  UNL, and severe when
ALT > 5  UNL. Disruption of chemotherapy treatment was
defined as either premature termination or a delay of more
than 8 days between cycles.Data extraction
Two reviewers (Liu and Sheng) independently applied
inclusion criteria, selected the studies, and extracted data
and outcomes. The following data were extracted from
each paper: (1) number of patients in the study; (2) details
of the study design; (3) patient characteristics; (4) treat-
ment regimen; and (5) outcome measures as defined
above. Disagreements were resolved by consensus. Authors
of the studies were contacted when clarification was
needed.Study quality
The quality of each study was independently assessed by
the same two reviewers (Liu and Sheng) using a seven-
question tool modified from the criteria used in Jadad
et al.28 We used a modified form because the tool described
in that paper was specific for randomized clinical trials.Figure 1 LiteratureWhen there was disagreement between the two reviewers,
a third party (Peng Hu) was consulted.
Statistical analysis
Meta-analysis was performed using Review Manager Soft-
ware 5.0 (Cochrane Collaboration, Oxford, UK) according to
the recommendations of the manufacturer and the Quality
of Reporting of Meta-analyses Guidelines.29 Statistical
analysis for dichotomous variables was carried out.
Heterogeneity was measured using the I-squared and chi-
squared test. In these tests, p < 0.05 was considered to
indicate statistical significance and p < 0.10 to indicate
significant heterogeneity. In cases where significant
heterogeneity existed, a random effect model was used for
analysis. A fixed effect model was used in the other cases.
Outcomes were expressed as relative risks (RR) with 95%
confidence intervals (CI). If the value 1 was not included in
the 95% CI, the point estimate of the RR was considered to
have reached statistical significance (p < 0.05).
Results
Search results and study characteristics
In all, 130 studies were identified and screened for retrieval
using the strategy described above. After screening the
title or abstract, 112 studies were excluded and 18 were
retrieved and subjected to detailed evaluation. Two studiessearch flow sheet.
Table 1 Characteristics of clinical trials included in the meta-analysis.
Study Area Study
type
Sample
Size (n)
Female
(n)
Mean
age (y)
Stage Median HBV-
DNA
quantitation
(copies/mL)
Liver function tests (range) Use of
cortico-
steroids
Chemotherapy
regimens
Median no. of
chemotherapy
cycles
received
(range)
Median ALT (U/L) Median TBIL
(mol/L)I II III IV AC AC/T CAF
Long et al.
(2011)
China RCTs T:21 21 45 (29e64) 10 8 2 1 6.16  106
(<1.00  103
e9.80107)
22.3 (7.0e96.0) 13.6 (5.6
e21.6)
NR 15 0 6 6 (4e8)
C:21 21 43 (20e62) 4 14 1 2 3.99  106
(<1.00  103
e8.28  107)
14.6 (6.0e27.0) 16.7 (6.4
e44.1)
NR 14 0 7 6 (1e8)
Tsai et al.
(2011)
Taiwan Cohort T:23 23 46 (34e61) NR NR NR NR NR 21.0 (3.0e52.0) NR 23 15 3 5 6 (2e7)
C:22 22 44 (32e59) NR NR NR NR NR 19.1 (8.0e39.0) NR 22 12 2 6 6 (3e7)
Yun et al.
(2011)
Korea Cohort T:55 55 48 (30e68) 9 32 14 0 NR 25.0 (11.0e55.0) 0.6 28 3 27 25 6 (1e9)
C:76 76 46 (30e69) 11 39 26 0 NR 25.0 (4.0e58.0) 0.5 33 17 31 28 6 (4e8)
Byeong et al.
(2005)
Korea Cohort T:41 41 48 (29e66) NR NR NR NR NR 18.0 (8.0e81.0) NR 40 21 20 0 4 (1e5)
C:128 128 46 (23e75) NR NR NR NR NR 14.6 (5.0e64.0) NR 111 82 46 0 5 (3e8)
Winnie et al.
(2004)
China Cohort T:31 31 46 (31e68) NR NR NR NR 7.07  104
(<1.00  103
e6.22  106)
28.0 (13.0e137.0) 6 (3.0e13.0) 23 28 3 0 6 (1e9)
C:61 61 46 (31e71) NR NR NR NR 5.88  104
(<1.00  103
e1.61  107)
27.0 (10.0e98.0) 6 (1.0e16.0) 36 49 12 0 6 (4e10)
Dai et al.
(2004)
Taiwan Cohort T:11 11 47 (36e58) 5 4 1 1 2.90  104
(<1.00  103
e3.40  105)
14.0 (12.0e31.0) NR NR 2 4 5 6 (2e7)
C:9 9 43 (27e55) 0 5 3 1 3.44  104
(<1.00  103
e9.80  106)
15.0 (6.0e54.0) NR NR 4 5 0 6 (3e8)
AC Z adriamycin þ cyclophosphamide; AC/T Z adriamycin þ cyclophosphamide followed by taxane; C Z no prophylaxis; CAF Z adriamycin þ cyclophosphamide þ fluorouracil;
NR Z not reported; RCTs Z randomized controlled trials; T Z lamivudine prophylaxis; TBIL Z total bilirubin.
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Figure 2 A funnel plot of all studies included in the meta-
analysis.
168 J.-Y. Liu et al.were excluded because of language, and 16 studies were
retained for further assessment. By using strict exclusion
criteria, 10 studies were eliminated by inclusion criteria.
Finally, six studies15,23e26,30 comprising a total of 499
patients were included in the meta-analysis (Fig. 1).
Of the six studies, one was a randomized controlled
trial,24 four were prospective cohort studies,15,23,25,30 and
one was a retrospective cohort study.26 All these studies
were published between 2004 and 2011. The basic charac-
teristics of each study are listed in Table 1. The populations
in the six studies were all Asian. The population size of the
studies ranged from 2015 to 169.26 The median patient age
ranged from 4315 to 4825 years old. The patients in the six
studies were all female, and had tested positive for HBsAg.
The mean HBV DNA levels varied from <1.00  103 to
6.16 106 copies/ml.24,25 Themedian ALT levels varied fromFigure 3 Comparison of HBV reactivation and occurren14 to 28 U/L. All patients in the studies underwent chemo-
therapeutic regimens of: adriamycin þ cyclophosphamide,
adriamycin þ cyclophosphamide followed by taxane, or
adriamycin þ cyclophosphamideþ fluorouracil. The median
chemotherapy cycles ranged from four26 to six.24 Cortico-
steroids were used in four studies.23,25,26,30 There were no
significant differences in the above-stated characteristics
between two groups from all six studies. All patients in the
prophylaxis group were given lamivudine 100 mg once per
day. Based on symmetrical funnel plot analyses, no evidence
of publication bias was found (Fig. 2).
Comparison of HBV reactivation rates between the
lamivudine prophylaxis and non-prophylaxis groups
All of the six studies reported HBV reactivation, which
included 182 patients in the lamivudine prophylaxis group,
and 317 patients in the non-prophylaxis group. Meta-
analysis revealed that patients with lamivudine prophy-
laxis had a significant reduction in the risk of HBV reac-
tivation (RR Z 0.23, 95% CI: 0.13e0.39, p < 0.00001;
Fig. 3). No significant heterogeneity was found (p Z 0.43),
and the fixed-effect model was applied. The exclusion of
any single study was found to not significantly alter the
overall pooled results, which ranged from 0.16 (95% CI:
0.15e0.47) to 0.24 (95% CI: 0.14e0.43; Table 2).
Comparison of hepatitis rates between lamivudine
prophylaxis and non-prophylaxis groups
All of the six studies reported the rates of hepatitis. The
occurrence rates of hepatitis attributable to HBV reac-
tivation in patients with lamivudine prophylaxis werece rates of hepatitis attributable to HBV reactivation.
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Lamivudine prophylaxis in hepatitis B reactivation 169significantly lower than the rates with no prophylaxis
(RR Z 0.20, 95% CI: 0.08e0.47, p Z 0.002; Fig. 3). There
was no significant heterogeneity in the data (p Z 0.13;
p Z 0.53), and the fixed effect model was applied. Four
studies23e26 reported the severity of hepatitis, of which 148
patients received lamivudine prophylaxis and 286 did not
receive any prophylaxis. The rates of moderate and severe
hepatitis in patients with lamivudine prophylaxis were
significantly lower than those with no prophylaxis
(RR Z 0.25, 95% CI: 0.10e0.62, p < 0.003; RR Z 0.25, 95%
CI: 0.10e0.59, p Z 0.002; Fig. 4). However, the rates of
mild hepatitis were comparable in the two groups
(RR Z 1.04, 95% CI: 0.61e1.70, p Z 0.88; Fig. 4). No
significant heterogeneity was found (p Z 0.24; p Z 0.55;
p Z 0.14), and the fixed effect model was used.
Comparison of chemotherapy disruptions between
the lamivudine prophylaxis and non-prophylaxis
groups
All six studies reported on disruptions of chemotherapy,
and completion of chemotherapy with a delay of 8 days
between cycles. Patients with lamivudine prophylaxis ach-
ieved a significant reduction in the overall rates of
chemotherapy disruptions and in the rates of delay of 8
days between cycles in those patients who completed
chemotherapy (RRZ 0.36, 95% CI: 0.21e0.64, pZ 0.0004;
RRZ 0.42, 95% CI: 0.21e0.82, pZ 0.01; Fig. 5). There was
no significant heterogeneity in the data (p Z 0.40;
p Z 0.87), and a fixed effect model was used.
Discussion
Studies have shown that hepatitis B reactivation following
cytotoxic chemotherapy or immunosuppressive therapy is
associated with a high rate of morbidity and mortality.31e33
In addition, HBV reactivation can be associated with early
chemotherapy discontinuation, and can thus potentially
increase mortality from the underlying malignancy.10,11,34
The current meta-analysis shows that patients with lam-
ivudine prophylaxis had significantly lower rates of
moderate and severe hepatitis compared to those with no
prophylaxis. The rates of mild hepatitis were comparable
between the two groups, however, suggesting that HBV
reactivation in patients undergoing chemotherapy tended
to be more closely associated with severe hepatitis. It is
therefore important to deal with the clinical problem to get
the maximum potential benefit from chemotherapy. In the
past, attention has been focused on patients with hema-
tological malignancies, especially in patients with
lymphoma, which was probably related to the frequent use
of high-dose corticosteroids in the standard combination
chemotherapy. Lamivudine prophylaxis prior to chemo-
therapy has therefore been recommended for these
patients.35e38 Little is known, however, about lamivudine
prophylaxis for HBV reactivation in patients with solid
tumor cancers.38e40 Several studies in patients with solid
tumors have suggested the efficacy of lamivudine prophy-
laxis treatment; however, these findings were based on the
results from patients with various tumor types and
chemotherapy regimens.41,42 In this meta-analysis, we
Figure 4 Comparison of the occurrence rates of hepatitis.
170 J.-Y. Liu et al.sought to evaluate the necessity of lamivudine prophylaxis
in HBsAg seropositive BC patients receiving similar chemo-
therapy regimens.
Several chemotherapeutic agents including steroids,
anthracyclines, and cyclophosphamide, which areFigure 5 Comparison of rates ocommonly used as components of BC chemotherapy regi-
mens, are associated with the development of HBV reac-
tivation. Anthracyclines and cyclophosphamide are usually
added to adriamycin/cyclophosphamide, adriamycin/
cyclophosphamide followed by taxane, or adriamycin/f disruption of chemotherapy.
Lamivudine prophylaxis in hepatitis B reactivation 171cyclophosphamide/fluorouracil combination chemotherapy
regimens. Corticosteroids, such as dexamethasone and
hydrocortisone, are commonly used with anthracyclines as
antiemetic drugs because anthracycline-containing regi-
mens often cause emesis.43e45
Various mechanisms of HBV reactivation in patients with
malignancy receiving chemotherapy are possible. First,
chemotherapy-induced immune myelosuppression may
enhance the rate of viral replication leading to enhanced
viral replication and widespread hepatocyte infection.12,46
Second, corticosteroids are generally believed to have
two effects: an immunosuppressive effect and direct
stimulation of viral replication via a glucocorticoid
responsive element in the enhancer region of the HBV
genome. Third, when chemotherapy is discontinued,
immune competence is restored, and the infected hepa-
tocytes may be rapidly destroyed.4,39,47,48
Initially, lamivudine was used in BC patients who had
developed ALT elevation due to HBV reactivation during
chemotherapy; however, that therapeutic strategy has
been reported to lead to fatal reactivation.4,49,50 Even if
patients do recover from this complication, their cancer
prognosis may be impaired by the disruption of chemo-
therapy.14,15,38,50,51 The strategy of lamivudine prophylaxis
was applied in several studies. However, several inconsis-
tencies were found in the outcomes of hepatitis flares and
HBV reactivations, reduction in the severity of hepatitis,
and disruption of chemotherapy between the lamivudine
prophylaxis group and the non-prophylaxis group in those
studies.15,23e26 Yun et al reported that patients with lam-
ivudine prophylaxis had significantly less HBV reactivation,
a lower hepatitis incidence, and fewer chemotherapy
disruptions than those with no prophylaxis (2% vs. 21%; 9%
vs. 33%; and 3% vs. 14%)25. A study by Yeo et al showed that
in the lamivudine prophylaxis group, there were signifi-
cantly fewer incidences of hepatitis, HBV reactivation, and
chemotherapy disruption than in the non-prophylaxis group
(12.9% vs. 59.0%; 6.5% vs. 31.1%; and 16.1% vs. 45.9%).23
Recently, however, a prospective and randomized
controlled study suggested that the incidence of hepatitis,
severity of hepatitis, chemotherapy disruptions, and over-
all mortality were not statistically different between the
groups. The current meta-analysis demonstrates that lam-
ivudine prophylaxis in HBsAg seropositive BC patients
undergoing chemotherapy is effective in reducing the rates
of HBV reactivation, hepatitis occurrence, and chemo-
therapy disruption.
Studies have demonstrated that viral replication occurs
1e2 weeks ahead of clinical hepatitis flare ups in cancer
patients,13,52,53 which may explain why prophylactic use of
lamivudine before the administration of chemotherapy is
more effective than its use when ALT elevation due to
HBV reactivation has already been detected during
chemotherapy. Although there is no consensus on the
optimal duration of lamivudine prophylaxis therapy, some
investigators have recommended that lamivudine should be
started at least 1 week before initiation, and be continued
until at least 6 weeks after the chemotherapy has been
completed.42,54 It is likely that the optimal timing and
duration of prophylaxis will depend in part on the antiviral
drug used as well as the intensity of the immunosuppres-
sion, and a number of host and viral factors.Although lamivudine is effective in HBV DNA suppres-
sion, liver enzyme normalization, and improvement of
histological features in HBeAg-positive and -negative/HBV
DNA-positive patients, studies included in the current
meta-analysis suggest that lamivudine prophylaxis reduces
the risk of HBV reactivation and prevents the associated
fatal hepatic complications with no myelosuppressive
effect in HBsAg seropositive BC patients already exposed to
immunosuppressive and cytotoxic agents. An important
limitation to the use lamivudine is the potential emergence
of lamivudine-resistant HBV strains, so-called ‘YMDD
mutations’, which can be associated with biochemical and
clinical flares. This antiviral agent should therefore be
cautiously administered, especially in those who require
extended periods of chemotherapy.55 Recently, newer
nucleoside analogues, such as adefovir, entecavir, tenofo-
vir, and telbivudine, have been approved for the treatment
of chronic hepatitis B, and have demonstrated sustained
treatment efficacy; some have low rates of viral resis-
tance.56 A study of a small-case series, for example,
recently demonstrated that entecavir was effective in the
prevention of HBV reactivation in cancer patients.57
Unfortunately, large prospective randomized trials on the
prophylactic use of these antiviral agents in BC patients
undergoing chemotherapy have been largely lacking.
Risk factors for HBV reactivation or acute exacerbation
in chemotherapy-treated patients have been postulated.
These include virological factors (high baseline HBV DNA
level, high baseline serum ALT level, positive tests for both
HBsAg and hepatitis B e antigen, and the presence of pre-
core mutant strain), host factors (male sex, younger age,
and lymphoma), and treatment factors (use of anthracy-
clines and steroids).58e62 Therefore, antiviral prophylaxis is
recommended for HBsAg-seropositive BC patients under-
going chemotherapy in view of the therapeutic efficacy and
safety of lamivudine, especially for those patients with high
risk factors as stated above.
There are several limitations to our meta-analysis that
should be considered before the generalization of our
findings. First, there was only one randomized controlled
trial included in our meta-analysis.24 The other five were
cohort studies. Second, all of the six studies were
composed exclusively of Asians. Third, the number of
studies included in this meta-analysis was small, and some
had small sample sizes. Fourth, the onset times and dura-
tions of lamivudine use were different, which probably
impacted the rates of HBV reactivation.
In conclusion, lamivudine prophylaxis in HBsAg-
seropositive BC patients undergoing chemotherapy is safe
and effective in reducing the occurrence of HBV reac-
tivation and HBV-associated morbidity and mortality. In
addition, patients who underwent prophylaxis therapy had
fewer interruptions and fewer premature terminations in
their chemotherapy. Prophylaxis should be considered for
BC patients who are known to be HbsAg-positive and plan to
undergo chemotherapy.Acknowledgments
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